Search results for "IBA"

showing 10 items of 1355 documents

Periodontal clinical and microbiological data in desquamative gingivitis patients.

2013

Objectives: A series of patients affected by desquamative gingivitis (DG) was investigated in order to evaluate relation patterns among clinical parameters relevant to plaque induced periodontitis, periodontal microbiological data and the presence of DG lesions. Patients and methods: Eight oral lichen planus (OLP) and four mucous membrane pemphigoid (MMP) patients were examined. Periodontal measurements (performed at six sites per tooth on all teeth) included probing depth (PD), gingival recession (REC), clinical attachment loss (CAL) and full mouth plaque (FMPS) and bleeding (FMBS) scores; the presence and the exact location (site by site) of DG lesions were carefully recorded. Sub-gingiva…

MaleDesquamative gingivitiMucous membrane pemphigoidSettore MED/50 - Scienze Tecniche Mediche ApplicateDentistrySettore MED/28 - Malattie OdontostomatologicheMedicineHumansGeneral DentistryGingival recessionAgedPeriodontitisbiologybusiness.industryPeriodontal pathogensSignificant differenceAggregatibacter actinomycetemcomitansMiddle Agedmedicine.diseasebiology.organism_classificationGingivitisDesquamative gingivitisstomatognathic diseasesPeriodontal statuOral lichen planuClinical attachment lossMucous membrane pemphigoidOral lichen planusFemalemedicine.symptombusinessClinical oral investigations
researchProduct

Efficacy and safety of combined diclofenac 0.1 % and gentamicin 0.3 eyedrops after phacoemulsification

1997

To study the efficacy of combined diclofenac 0.1% and gentamicin 0.3% (Digen) eyedrops to treat postoperative inflammation and prevent ocular infection in eyes having phacoemulsification.Department of Ophthalmology, University of Milan, San Paolo Hospital, Milan; Eye Clinic, University of Verona; and Department of Ophthalmology, University of Palermo, Italy.This double-masked, randomized, clinical trial comprised 90 patients; 45 received Digen and 45, gentamicin 0.3% eyedrops. The main outcome measure of the study was the reduction in signs and symptoms of inflammation, graded on a four-point scale. Also assessed were the presence of bacteria in the conjunctival swab and the proportion of p…

MaleDiclofenacAdministration Topicalmedicine.medical_treatmentEye diseaseEye Infections BacterialDiclofenacDouble-Blind MethodmedicineHumansAgedRetrospective StudiesAntibacterial agentAged 80 and overEndophthalmitisPhacoemulsificationbusiness.industryAnti-Inflammatory Agents Non-SteroidalAminoglycosideEye dropPhacoemulsificationMiddle Agedmedicine.diseaseSensory SystemsAnti-Bacterial AgentsClinical trialOphthalmologyTreatment OutcomeAnesthesiaDrug Therapy CombinationFemaleSurgeryGentamicinGentamicinsOphthalmic SolutionsSafetybusinessmedicine.drugJournal of Cataract and Refractive Surgery
researchProduct

Pharmacokinetics, bioavailability and absorption of flumequine in the rat.

1999

Abstract The study demonstrates that the oral extent of bioavailability of flumequine in the rat, relative to the intravenous injection, is complete (0.94±0.04) and not significantly different from that found by the intraduodenal route (0.95±0.04). The rate of oral bioavailability, however, is slow ( k a =1.20±0.07 h −1 ; T max =2.0 h), but enough to maintain plasma levels above the minimal inhibitory concentration of the most common pathogens for an extended period of time (about 10 h). The reason for the oral absorption slowness could be a slow gastric emptying, an adsorption to the gastric mucosae, a precipitation in the gastric medium or any other feature concerning the stomach as the i…

MaleDuodenumPharmaceutical ScienceAdministration OralBiological AvailabilityPharmacologyModels BiologicalRandom AllocationPharmacokineticsAnti-Infective AgentsOral administrationEnterohepatic CirculationmedicineAnimalsRats WistarEnterohepatic circulationAntibacterial agentGastric emptyingChemistryStomachGeneral MedicineBioavailabilityRatsmedicine.anatomical_structureIntestinal AbsorptionFlumequineQuinolizinesBiotechnologymedicine.drugFluoroquinolonesEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Modulation of epitope-specific anti-hepatitis C virus E2 (anti-HCV/E2) antibodies by antiviral treatment

2006

The dynamic features of three specific anti-hepatitis C virus (HCV) antibody subpopulations directed against different conformational epitopes of the viral E2 protein (HCV/E2) have been evaluated in patients with primary and persistent HCV infection; the three subpopulations are present in patients infected with different HCV genotypes and have shown a different activity using a pseudovirus neutralization assay (antibodies e301 and e137 exhibiting high neutralizing activity, while antibody e509 enhancement of HCV infectivity). In sequential samples from five patients with primary HCV infection and different virological outcome, all samples tested negative with the single exception of the e5…

MaleEpitope-specific response; HCV/E2 glycoprotein; Human monoclonal antibodies; Therapeutic responseTime FactorsSettore MED/42 - Igiene Generale e ApplicataMolecular ConformationHepacivirusmedicine.disease_causeEpitopePolyethylene GlycolsEpitopeschemistry.chemical_compoundViral Envelope ProteinsAntibody SpecificityHCV/E2 glycoproteinNeutralizing antibodyInfectivitybiologyViral Core ProteinsMiddle AgedHepatitis CEpitope-specific responseTreatment OutcomeInfectious DiseasesDisease ProgressionDrug Therapy CombinationFemaleAntibodyAdultmedicine.drug_classHepatitis C virusMonoclonal antibodyAntiviral AgentsVirusNeutralization TestsVirologyRibavirinmedicineHumansViremiaRibavirintherapeutic responseInterferon-alphaHepatitis C AntibodiesVirologyHuman monoclonal antibodieschemistryImmunologybiology.proteinhuman monoclonal antibodietope-specific response5' Untranslated Regions
researchProduct

Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein

2011

<i>Background:</i> ADAM10 (a disintegrin and metalloproteinase 10) has been demonstrated to act as the main physiological α-secretase. Enzymatic activity of the α-secretase on the one hand prevents the formation of toxic Aβ peptides and on the other hand promotes the secretion of a neurotrophic and neuroprotective amyloid precursor protein fragment (APPs-α) by cleaving the amyloid precursor protein within its Aβ sequence. Enhancement of ADAM10’s gene expression may therefore present a valuable therapeutic approach for the treatment of Alzheimer’s disease (AD), where Aβ peptides are severely involved in the pathogenesis. <i>Objective:</i> In cell culture and in a tran…

MaleGenetically modified mouseATP Binding Cassette Transporter Subfamily BTime FactorsADAM10PharmacologyTransfectionAcitretinADAM10 ProteinMiceNeuroblastomachemistry.chemical_compoundCell Line TumormedicineAmyloid precursor proteinAnimalsHumansATP Binding Cassette Transporter Subfamily B Member 1Chromatography High Pressure LiquidP-glycoproteinMice KnockoutAnalysis of VarianceReporter genebiologyMembrane ProteinsMolecular biologyAcitretinADAM ProteinsGene Expression RegulationNeurologychemistryAlpha secretaseBlood-Brain Barrierbiology.proteinTamibaroteneNeurology (clinical)Amyloid Precursor Protein Secretasesmedicine.drugNeurodegenerative Diseases
researchProduct

Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection.

2011

Background Several works observed a link between uric acid serum levels and clinical and histological features of nonalcoholic fatty liver disease. An association between chronic hepatitis C (CHC) and uric acid levels has been poorly investigated. Aims To assess the potential association between uric acid serum levels and both histological features of liver damage and sustained virological response (SVR) in a homogeneous cohort of CHC patients. Methods Consecutive biopsy-proven CHC patients were included. Hyperuricaemia was diagnosed with uric acid serum levels >7 mg/dl in men, and >6 mg/dl in women. Patients underwent therapy with pegylated interferon plus ribavirin. Results Hyperuricaemia…

MaleHCV STEATOSIS HYPERURICEMIAmedicine.medical_specialtyBiopsyRenal functionHepacivirusHyperuricemiaSettore MED/08 - Anatomia PatologicaGastroenterologychemistry.chemical_compoundPegylated interferonInternal medicineNonalcoholic fatty liver diseasemedicineHumansSettore MED/12 - GastroenterologiaHepatologybusiness.industryRibavirinHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisUric AcidFatty LiverEndocrinologychemistryUric acidFemaleSteatosisbusinessBody mass indexBiomarkersmedicine.drug
researchProduct

Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis.

2013

Summary We assessed, in real-life practice, viral, demographic, genetic and metabolic factors influencing the sustained virologic response (SVR), with a gender-oriented analysis, in patients with chronic hepatitis C virus (HCV) treated with pegylated interferon and ribavirin. Six hundred and seventy naive patients were treated with dual therapy and evaluated by gender and HCV genotype. Associations between baseline variables and SVR were assessed by multivariate logistic regression analysis. Among 362 genotype 1 patients, SVR was achieved in 158 patients (44%), and SVR was independently associated with age less than 50 years (OR 2.12; 95% CI 1.09–4.30; P = 0.039) and C/C genotype rs12979860…

MaleHCV-RNA levelsHepacivirusHepacivirusLogistic regressionGastroenterologyCohort Studieschemistry.chemical_compoundPegylated interferonGenotypeantiviral therapygenderProspective Studiespeg-interferon and ribavirinProspective cohort studybiologysustained virologic responsevirus diseaseschronic hepatitis C; gender; HCV-RNA levels; IL28B polymorphisms; peg-interferon and ribavirin; sustained virologic responseMiddle AgedViral LoadTreatment OutcomeInfectious DiseasesDrug Therapy CombinationFemaleViral loadHCV-RNA levels; IL28B polymorphisms; chronic hepatitis C; gender; peg-interferon and ribavirin; sustained virologic response; Adult; Aged; Cohort Studies; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Male; Middle Aged; Prospective Studies; Ribavirin; Sex Factors; Treatment Outcome; Viral Loadmedicine.drugAdultmedicine.medical_specialtySex FactorsVirologyInternal medicineRibavirinmedicineHumanschronic hepatitis CRapid Virologic ResponseAgedHepatologybusiness.industryRibavirinHepatitis C Chronicbiology.organism_classificationdigestive system diseaseschemistryImmunologyInterferonsIL28B polymorphismsbusiness
researchProduct

Maintaining everyday life praxis in the time of COVID-19 pandemic measures (ELP-COVID-19 survey)

2020

Abstract Background The extreme social circumstances caused by declared COVID-19 pandemic deeply intervene people’s everyday life and should not be neglected but seen through the view of social reality pinpointing the ‘ordinary’ people. In this article, authors explored basic segments of everyday and their subjective perception to what extent sleeping habits, physical inactivity, physical activity, nutritional habits and smoking have changed. Methods The online survey was conducted in nine European countries (Bosnia and Herzegovina, Croatia, Greece, Kosovo*, Italy, Serbia, Slovakia, Slovenia and Spain) in 4108 participants, aged 15–82 years. The survey took place 30–40 days after World Heal…

MaleHealth Behaviordaily life praxispandemijephysical activitygibanje0302 clinical medicinePandemic030212 general & internal medicineYoung adultEveryday lifemedia_commonAged 80 and overživljenjski stilPublic healtheducation.field_of_studyPraxisudc:316.728:616-036.21SmokingCOVID-19 pandemic measurespublic healthsleeping habitsMiddle AgedEuropeAdolescent Adult Aged 80 and over COVID-19 Europe Exercise Feeding Behavior Female Humans Male Middle Aged Pandemics SARS-CoV-2 Screen Time Sleep Smoking Young Adult Health Behavior Life StyleFemalePsychologyAcademicSubjects/SOC02610AdultCoronavirus disease 2019 (COVID-19)Adolescentmedia_common.quotation_subjectPopulationspalne navadeOriginal Manuscriptphysical activity ; smoking ; lack of exercise ; alcohol drinking ; sports ; World Health Organization ; eating ; sleep ; pandemics ; screen time ; containment ; healthy lifestyle ; coronavirus pandemicScreen Time03 medical and health sciencesScreen timeYoung AdultSleeping habitsHumansAcademicSubjects/MED00860AcademicSubjects/SOC01210educationExerciseLife StylePandemicscoronavirus pandemicAgedConsumption (economics)Daily life praxisPhysical activitySARS-CoV-2koronavirusjavno zdravjePublic Health Environmental and Occupational HealthEating habitsCOVID-19eating habitsFeeding BehaviorCOVID-19 ukrepiprehranjevalne navadeSleepgibalna aktivnost030217 neurology & neurosurgeryDemography
researchProduct

Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors.

2010

Background Current treatment of chronic hepatitis C virus (HCV) infection has limited efficacy −especially among genotype 1 infected patients−, is costly, and involves severe side effects. Thus, predicting non-response is of major interest for both patient wellbeing and health care expense. At present, treatment cannot be individualized on the basis of any baseline predictor of response. We aimed to identify pre-treatment clinical and virological parameters associated with treatment failure, as well as to assess whether therapy outcome could be predicted at baseline. Methodology Forty-three HCV subtype 1b (HCV-1b) chronically infected patients treated with pegylated-interferon alpha plus ri…

MaleHepaciviruslcsh:MedicineHepacivirusmedicine.disease_causePolyethylene Glycolschemistry.chemical_compoundlcsh:ScienceMultidisciplinarybiologyDiscriminant AnalysisHepatitis CMiddle AgedViral LoadPrognosisHepatitis CRecombinant ProteinsTreatment OutcomeGastroenterology and Hepatology/Gastrointestinal InfectionsDrug Therapy CombinationFemaleViral hepatitisViral loadResearch ArticleAdultmedicine.medical_specialtyCombination therapyHepatitis C virusAlpha interferonInterferon alpha-2Antiviral AgentsGastroenterology and Hepatology/HepatologyInternal medicineRibavirinInfectious Diseases/Viral InfectionsmedicineHumansRetrospective StudiesVirology/Antivirals including Modes of Action and ResistanceInfectious Diseases/Antimicrobials and Drug Resistancebusiness.industryRibavirinlcsh:RGenetic VariationInterferon-alphaMicrobiology/Medical MicrobiologyVirology/Mechanisms of Resistance and Susceptibility including Host Geneticsmedicine.diseasebiology.organism_classificationLogistic ModelschemistryImmunologylcsh:QbusinessPLoS ONE
researchProduct

Insulin resistance and diabetes mellitus in patients with chronic hepatitis C: spectators or actors?

2012

MaleHepatologybusiness.industryHepatitis C virusGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseasemedicine.disease_causeAntiviral AgentsRecombinant ProteinsPolyethylene GlycolsInsulin resistanceChronic hepatitisDiabetes Mellitus Type 2Diabetes mellitusImmunologyRibavirininsulin resistance diabetes hcvmedicineHumansIn patientFemaleInsulin Resistancebusiness
researchProduct